^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCDC6‐RET fusion + TERT promotor mutation

    i
    Other names: CCDC6, Coiled-Coil Domain Containing 6, Papillary Thyroid Carcinoma-Encoded Protein, Coiled-Coil Domain-Containing Protein 6, D10S170, TST1, DNA Segment Single Copy Probe PH4 (Transforming Sequence Thyroid-1, DNA Segment On Chromosome 10 (Unique) 170, Protein H4, PTC, TPC, H4, RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1, TERT, Telomerase Reverse Transcriptase, Telomerase-Associated Protein 2, Telomerase Catalytic Subunit, HEST2, EST2, TCS1, TP2, TRT, PFBMFT1, DKCA2, DKCB4, CMM9, HTR
    Entrez ID:
    5979; 7015; 8030
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    8ms
    A CASE OF RET POSITIVE METASTATIC ANAPLASTIC THYROID CARCINOMA WITH EXCELLENT RESPONSE TO RET INHIBITOR THERAPY (ATA 2023)
    After the initiation of Selpercatinib, subsequent 3 month interval imaging revealed near complete resolution of her disease. We present a unique case of a young woman with metastatic ATC and an excellent response to targeted RET inhibition.
    Clinical • Late-breaking abstract • Metastases
    |
    RET (Ret Proto-Oncogene) • TERT (Telomerase Reverse Transcriptase) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    RET mutation • TERT mutation • CCDC6‐RET fusion + TERT promotor mutation • RET positive
    |
    Retevmo (selpercatinib)